PeptideMark

Safety Profile

Semaglutide Side Effects: Frequency & Severity

Semaglutide has one of the most extensively documented safety profiles in peptide medicine, with over a decade of clinical use. GI effects predominate and are usually transient.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Black Box Warning

Risk of thyroid C-cell tumors observed in rodent studies. Human relevance is unknown. Contraindicated in patients with personal or family history of MTC or MEN 2.

Serious side effects

1

  • Medullary thyroid carcinoma (MTC)

    Observed in rodents; human relevance uncertain. Black box warning.

Common side effects

5

  • Nausea

    20-44%

    Most common side effect. Typically peaks in first 4-8 weeks and resolves with continued use.

  • Diarrhea

    30%

    Dose-related; usually mild to moderate.

  • Vomiting

    9-24%

    More common at higher doses and during titration.

  • Constipation

    11-24%

    Due to slowed gastric and intestinal transit.

  • Abdominal pain

    12-20%

    Usually mild; persistent severe pain warrants evaluation.

Uncommon side effects

4

  • Injection site reactions

    <10%

    Redness, itching, mild swelling at injection site.

  • Fatigue

    Reported in early weeks of therapy.

  • Headache

    Typically transient.

  • Gallbladder disease

    ~2%

    Including cholelithiasis and cholecystitis. Risk increases with rapid weight loss.

Rare side effects

4

  • Acute pancreatitis

    <1%

    Presents with severe persistent abdominal pain radiating to back. Discontinue if suspected.

  • Diabetic retinopathy complications

    In patients with pre-existing retinopathy. Monitor in T2D patients.

  • Acute kidney injury

    Usually related to volume depletion from severe GI symptoms.

  • Severe hypoglycemia

    Uncommon as monotherapy; increased risk with insulin or sulfonylureas.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Prior hypersensitivity to semaglutide or any component

Drug interactions

  • Insulin and sulfonylureas — increased hypoglycemia risk; may require dose reduction
  • Oral medications — delayed gastric emptying may alter absorption of concurrently administered drugs
  • Warfarin — monitor INR more frequently when starting or adjusting

Special populations

Not recommended in pregnancy (weight-loss indication) due to potential fetal harm. Limited pediatric data under age 12; approved down to age 12 for obesity. No specific dose adjustments for elderly.

Overall safety summary

Semaglutide has a favorable overall safety profile validated by multiple cardiovascular outcome trials (SUSTAIN-6, SELECT) and large real-world cohorts. Most adverse events are GI and self-limiting. Serious events are rare but include pancreatitis and gallbladder disease.

Semaglutide side effects: FAQ

Are semaglutide side effects permanent?

Most common side effects resolve within 4-8 weeks of starting or titrating. GI symptoms typically improve as the body adapts. Serious adverse events are rare.

Can semaglutide cause thyroid cancer?

Rodent studies showed C-cell tumor development. Human epidemiological data has not confirmed this risk. The FDA maintains a black-box warning out of caution.

Back to Semaglutide profileLegal statusResearch timeline